HRP20161141T1 - Anti-il-23 protutijela - Google Patents
Anti-il-23 protutijela Download PDFInfo
- Publication number
- HRP20161141T1 HRP20161141T1 HRP20161141TT HRP20161141T HRP20161141T1 HR P20161141 T1 HRP20161141 T1 HR P20161141T1 HR P20161141T T HRP20161141T T HR P20161141TT HR P20161141 T HRP20161141 T HR P20161141T HR P20161141 T1 HRP20161141 T1 HR P20161141T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- amino acid
- acid sequence
- seq
- antigen
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 50
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 25
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Claims (26)
1. Humanizirano anti-IL-23p19 protutijelo ili njegov antigen-vezujući fregment, pri čemu protutijelo ili njegov antigen-vezujući fregment obuhvaćaju:
a) varijabilnu regiju lakog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 19 (CDR1-L), aminokiselinski slijed SEQ ID NO: 20 (CDR2-L); i aminokiselinski slijed SEQ ID NO : 21 (CDR3-L), i
b) varijabilnu regiju teškog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 66 ili 67 (CDR1-H), aminokiselinski slijed SEQ ID NO: 64 (CDR2-H); i aminokiselinski slijed SEQ ID NO : 65 (CDR3-H).
2. Humanizirano anti-IL-23p19 protutijelo ili njegov antigen-vezujući fregment u skladu s patentnim zahtjevom 1, pri čemu protutijelo ili njegov antigen-vezujući fregment obuhvaćaju:
a) varijabilnu regiju lakog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 19 (CDR1-L), aminokiselinski slijed SEQ ID NO: 20 (CDR2-L); i aminokiselinski slijed SEQ ID NO : 21 (CDR3-L), i
b) varijabilnu regiju teškog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 66 (CDR1-H), aminokiselinski slijed SEQ ID NO: 64 (CDR2-H); i aminokiselinski slijed SEQ ID NO : 65 (CDR3-H).
3. Humanizirano anti-IL-23p19 protutijelo ili njegov antigen-vezujući fregment u skladu s patentnim zahtjevom 1, pri čemu protutijelo ili njegov antigen-vezujući fregment obuhvaćaju:
a) varijabilnu regiju lakog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 19 (CDR1-L), aminokiselinski slijed SEQ ID NO: 20 (CDR2-L); i aminokiselinski slijed SEQ ID NO : 21 (CDR3-L), i
b) varijabilnu regiju teškog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 67 (CDR1-H), aminokiselinski slijed SEQ ID NO: 64 (CDR2-H); i aminokiselinski slijed SEQ ID NO : 65 (CDR3-H).
4. Humanizirano anti-IL-23p19 protutijelo ili njegov antigen-vezujući fregment u skladu s patentnim zahtjevom 1, pri čemu protutijelo ili njegov antigen-vezujući fregment obuhvaćaju varijabilnu regiju lakog lanca koja sadrži aminokiselinski slijed bilo kojeg od SEQ ID NO: 158, 160, 162 ili 164; i varijabilnu regiju teškog lanca koja sadrži aminokiselinski slijed bilo kojeg od SEQ ID NO: 166 ili 168.
5. Humanizirano anti-IL-23p19 protutijelo ili njegov antigen-vezujući fregment u skladu s patentnim zahtjevom 4, pri čemu protutijelo ili njegov antigen-vezujući fregment obuhvaćaju varijabilnu regiju lakog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 160 i varijabilnu regiju teškog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 166.
6. Humanizirano anti-IL-23p19 protutijelo ili njegov antigen-vezujući fregment u skladu s patentnim zahtjevom 4, pri čemu protutijelo ili njegov antigen-vezujući fregment obuhvaćaju varijabilnu regiju lakog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 160 i varijabilnu regiju teškog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 168.
7. Humanizirano anti-IL-23p19 protutijelo ili njegov antigen-vezujući fregment u skladu s patentnim zahtjevom 4, pri čemu protutijelo ili njegov antigen-vezujući fregment obuhvaćaju varijabilnu regiju lakog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 158 i varijabilnu regiju teškog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 166.
8. Humanizirano anti-IL-23p19 protutijelo ili njegov antigen-vezujući fregment u skladu s patentnim zahtjevom 4, pri čemu protutijelo ili njegov antigen-vezujući fregment obuhvaćaju aminokiselinski slijed SEQ ID NO: 166 ili 168 vezan za ljudsku konstantnu regiju IgG1 teškog lanca; i aminokiselinski slijed SEQ ID NO: 158 ili 160 vezan za ljudsku konstantnu regiju kappa lakog lanca.
9. Humanizirano anti-IL-23p19 protutijelo ili njegov antigen-vezujući fregment u skladu s patentnim zahtjevom 1, pri čemu protutijelo ili njegov antigen-vezujući fregment obuhvaćaju:
a) humaniziranu varijabilnu domenu lakog lanca koja sadrži CDR-ove sa SEQ ID NO: 158 ili 160 i regije okvira koje imaju aminokiselinski slijed najmanje 90% identičan aminokiselinskom slijedu regija okvira varijabilne domene lakog lanca aminokiselinskog slijeda SEQ ID NO: 158 ili 160; i
b) humaniziranu varijabilnu domenu teškog lanca koja sadrži CDR-ove sa SEQ ID NO: 166 ili 168 i regije okvira koje imaju aminokiselinski slijed najmanje 90% identičan aminokiselinskom slijedu regija okvira varijabilne domene teškog lanca aminokiselinskog slijeda SEQ ID NO: 166 ili 168.
10. Humanizirano anti-IL-23p19 protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, pri čemu je protutijelo monoklonsko protutijelo.
11. Humanizirano anti-IL-23p19 protutijelo u skladu s patentnim zahtjevom 1, pri čemu je protutijelo monoklonsko protutijelo anti-IL-23p19 koje sadrži laki lanac koji sadrži aminokiselinski slijed SEQ ID NO: 174 ili 180 i teški lanac koji sadrži aminokiselinski slijed SEQ ID NO: 176 ili 178.
12. Humanizirano anti-IL-23p19 protutijelo u skladu s patentnim zahtjevom 11, pri čemu navedeno protutijelo sadrži laki lanac koji sadrži aminokiselinski slijed SEQ ID NO: 174 i teški lanac koji sadrži aminokiselinski slijed SEQ ID NO: 176.
13. Humanizirano anti-IL-23p19 protutijelo u skladu s patentnim zahtjevom 11, pri čemu navedeno protutijelo sadrži laki lanac koji sadrži aminokiselinski slijed SEQ ID NO: 174 i teški lanac koji sadrži aminokiselinski slijed SEQ ID NO: 178.
14. Humanizirano anti-IL-23p19 protutijelo u skladu s patentnim zahtjevom 11, pri čemu navedeno protutijelo sadrži laki lanac koji sadrži aminokiselinski slijed SEQ ID NO: 180 i teški lanac koji sadrži aminokiselinski slijed SEQ ID NO: 176.
15. Protutijelo ili antigen-vezujući fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 14 za uporabu u medicini.
16. Protutijelo ili antigen-vezujući fragment u skladu s patentnim zahtjevom 15, pri čemu je uporaba tretiranje upalne bolesti, autoimune bolesti, respiratorne bolesti, metaboličkog poremećaja ili raka.
17. Protutijelo ili antigen-vezujući fragment u skladu s patentnim zahtjevom 16, pri čemu je uporaba tretiranje psorijaze, upalne bolesti crijeva, psorijatičnog artrirtisa, multiple skleroze, reumatoidnog artritisa, Chronove bolesti, ulceroznog kolitisa ili ankilozantnog spondilitisa.
18. Protutijelo ili antigen-vezujući fragment u skladu s patentnim zahtjevom 16, pri čemu je uporaba tretiranje astme ili COPD (kronične opstruktivne bolesti pluća).
19. Farmaceutski sastav obuhvaća protutijelo ili antigen-vezujući fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 14 i farmaceutski prihvatljivi nosač.
20. Izolirani polinukleotid obuhvaća slijed koji kodira varijabilnu regiju lakog lanca protutijela ili fragmenta protutijela koji ima aminokiselinski slijed SEQ ID NO: 158, 160, 162 ili 164 i koji kodira varijabilnu regiju teškog lanca protutijela ili fragmenta protutijela koji ima aminokiselinski slijed SEQ ID NO: 166 ili 168.
21. Izolirani polinukleotid u skladu s patentnim zahtjevom 20, pri čemu navedeni polinukleotid obuhvaća slijed koji kodira varijabilnu regiju lakog lanca protutijela ili fragmenta protutijela koji ima aminokiselinski slijed SEQ ID NO: 174 ili 180 i koji kodira varijabilnu regiju teškog lanca protutijela ili fragmenta protutijela koji ima aminokiselinski slijed SEQ ID NO: 176 ili 178.
22. Ekspresijski vektor koji obuhvaća polinukleotid iz patentnog zahtjeva 20 ili 21.
23. Stanica domaćin obuhvaća:
a) izolirani polinukleotid koji sadrži slijed koji kodira varijabilnu regiju lakog lanca protutijela ili fragmenta protutijela koji ima aminokiselinski slijed SEQ ID NO: 158, 160, 162 ili 164; i
b) izolirani polinukleotid koji sadrži slijed koji kodira varijabilnu regiju teškog lanca protutijela ili fragmenta protutijela koji ima aminokiselinski slijed SEQ ID NO: 166 ili 168.
24. Stanica domaćin obuhvaća:
a) izolirani polinukleotid koji sadrži slijed koji kodira laki lanac protutijela koji ima aminokiselinski slijed SEQ ID NO: 174 ili 180; i
b) izolirani polinukleotid koji sadrži slijed koji kodira teški lanac protutijela koji ima aminokiselinski slijed SEQ ID NO: 176 ili 178.
25. Metoda za stvaranje protutijela ili antigen-vezujućeg fragmenta obuhvaća:
a) dobivanje stanice domaćina u skladu s patentnim zahtjevom 23 ili 24; i
b) kultiviranje stanice domaćina.
26. Metoda u skladu s patentnim zahtjevom 25, nadalje obuhvaća obnavljanje i pročišćavanje protutijela ili antigen-vezujućeg fragmenta.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41015810P | 2010-11-04 | 2010-11-04 | |
| US41195310P | 2010-11-10 | 2010-11-10 | |
| US41259410P | 2010-11-11 | 2010-11-11 | |
| US201161448785P | 2011-03-03 | 2011-03-03 | |
| EP11781949.0A EP2635601B1 (en) | 2010-11-04 | 2011-11-02 | Anti-il-23 antibodies |
| PCT/US2011/058869 WO2012061448A1 (en) | 2010-11-04 | 2011-11-02 | Anti-il-23 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161141T1 true HRP20161141T1 (hr) | 2016-12-02 |
Family
ID=44936573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161141TT HRP20161141T1 (hr) | 2010-11-04 | 2016-09-06 | Anti-il-23 protutijela |
Country Status (39)
| Country | Link |
|---|---|
| US (5) | US8778346B2 (hr) |
| EP (4) | EP3456740A1 (hr) |
| JP (3) | JP6126532B2 (hr) |
| KR (2) | KR102049223B1 (hr) |
| CN (2) | CN103282382B (hr) |
| AP (1) | AP3953A (hr) |
| AR (1) | AR083747A1 (hr) |
| AU (3) | AU2011323426B2 (hr) |
| BR (1) | BR112013011065B1 (hr) |
| CA (2) | CA3017116A1 (hr) |
| CO (1) | CO6801628A2 (hr) |
| CY (2) | CY1118014T1 (hr) |
| DK (1) | DK2635601T3 (hr) |
| EA (2) | EA030436B1 (hr) |
| EC (1) | ECSP13012649A (hr) |
| ES (1) | ES2593754T3 (hr) |
| GE (1) | GEP201706733B (hr) |
| HK (1) | HK1247940A1 (hr) |
| HR (1) | HRP20161141T1 (hr) |
| HU (2) | HUE030916T2 (hr) |
| IL (2) | IL225648A (hr) |
| LT (2) | LT2635601T (hr) |
| LU (1) | LUC00132I2 (hr) |
| MA (1) | MA34641B1 (hr) |
| ME (1) | ME02499B (hr) |
| MX (3) | MX2019000046A (hr) |
| MY (1) | MY162791A (hr) |
| NL (1) | NL301013I2 (hr) |
| NO (1) | NO2019038I1 (hr) |
| NZ (1) | NZ610592A (hr) |
| PE (1) | PE20141162A1 (hr) |
| PL (1) | PL2635601T3 (hr) |
| PT (1) | PT2635601T (hr) |
| RS (1) | RS55161B1 (hr) |
| SG (2) | SG190006A1 (hr) |
| SI (1) | SI2635601T1 (hr) |
| TW (2) | TWI545133B (hr) |
| UY (1) | UY33703A (hr) |
| WO (1) | WO2012061448A1 (hr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| EP3456740A1 (en) | 2010-11-04 | 2019-03-20 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
| US11078265B2 (en) * | 2012-05-03 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Anti-IL-23 antibodies |
| AR094877A1 (es) * | 2013-03-08 | 2015-09-02 | Lilly Co Eli | Anticuerpos que se unen a il-23 |
| SG10201804954UA (en) | 2013-03-15 | 2018-07-30 | Amgen Inc | Methods for treating psoriasis using an anti-il-23 antibody |
| CA2906384A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Methods for treating crohn's disease using an anti-il23 antibody |
| JP2017524359A (ja) * | 2014-07-24 | 2017-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー |
| EA039598B9 (ru) | 2014-09-03 | 2022-03-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23а и фно-альфа, и его применение |
| CA2972995A1 (en) * | 2015-02-04 | 2016-08-11 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| BR112017018574A2 (pt) | 2015-04-14 | 2018-04-17 | Boehringer Ingelheim International Gmbh | métodos para o tratamento de doenças |
| KR102644875B1 (ko) | 2015-07-23 | 2024-03-06 | 베링거잉겔하임인터내쇼날유한회사 | Il-23a 및 b-세포 활성화 인자(baff)를 표적화하는 화합물 및 이의 용도 |
| BR112018005175A2 (pt) | 2015-09-17 | 2018-10-16 | Amgen Inc | predição de resposta clínica a antagonistas de il23 usando biomarcadores de via de il23 |
| TWI811716B (zh) * | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
| CN108697791B (zh) * | 2015-11-03 | 2022-08-23 | 詹森生物科技公司 | 特异性结合pd-1的抗体及其用途 |
| US11220541B2 (en) | 2015-12-22 | 2022-01-11 | Amgen Inc. | CCL20 as a predictor of clinical response to IL23-antagonists |
| AU2017250583A1 (en) | 2016-04-15 | 2018-08-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| US20180105588A1 (en) * | 2016-10-14 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
| US20210030735A1 (en) * | 2018-02-05 | 2021-02-04 | Tesaro, Inc. | Pediatric niraparib formulations and pediatric treatment methods |
| TWI744617B (zh) * | 2018-03-30 | 2021-11-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
| AU2019300491A1 (en) | 2018-07-13 | 2021-03-04 | Astrazeneca Collaboration Ventures, Llc | Treating ulcerative colitis with brazikumab |
| CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
| CN109810947B (zh) * | 2019-01-18 | 2021-06-11 | 北京贝来生物科技有限公司 | 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用 |
| MA55729A (fr) * | 2019-04-15 | 2022-02-23 | Sun Pharmaceutical Ind Ltd | Procédés de traitement de sujets atteints d'arthrite psoriasique |
| AU2020409124A1 (en) | 2019-12-20 | 2022-06-30 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| CN111956606B (zh) * | 2020-08-31 | 2021-05-14 | 江苏荃信生物医药有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂 |
| TW202224702A (zh) | 2020-09-10 | 2022-07-01 | 美商美國禮來大藥廠 | 治療性抗體調配物 |
| KR20230086765A (ko) * | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
| CA3219846A1 (en) | 2021-05-28 | 2022-12-01 | Venkatesh Krishnan | Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis |
| KR20230009815A (ko) | 2021-07-09 | 2023-01-17 | 연세대학교 산학협력단 | Il-23에 의해 매개되는 질환의 중증도 예측용 조성물 |
| WO2023056417A1 (en) | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
| WO2024077113A1 (en) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Methods of treating fatigue in ulcerative colitis |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ATE161192T1 (de) | 1992-08-21 | 1998-01-15 | Genentech Inc | Verfahren zur behandlung einer durch lfa-1 vermittelten störung |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
| WO1999040195A1 (en) | 1998-02-06 | 1999-08-12 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
| ATE474849T1 (de) | 1998-04-14 | 2010-08-15 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
| US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| ES2300276T5 (es) | 1999-09-09 | 2017-06-02 | Merck Sharp & Dohme Corp. | P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas |
| US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| ES2307618T3 (es) | 2000-05-10 | 2008-12-01 | Schering Corporation | Proteinas subunidades de receptores de cotocinas de mamiferos, reactivos y metodos relacionados. |
| JPWO2003034818A1 (ja) | 2001-10-24 | 2005-02-10 | 中外製薬株式会社 | Ｓｇｒｆ遺伝子改変非ヒト動物 |
| CA2466034C (en) | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| CA2501786C (en) | 2002-10-30 | 2015-02-17 | Genentech, Inc. | Inhibition of il-17 production |
| ES2367302T3 (es) | 2002-12-23 | 2011-11-02 | Schering Corporation | Usos de la citoquina il-23 de mamífero; reactivos relacionados. |
| WO2004071517A2 (en) | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
| TWI357336B (en) | 2003-03-10 | 2012-02-01 | Schering Corp | Uses of il-23 agonists and antagonists; related re |
| US7413894B2 (en) | 2003-07-01 | 2008-08-19 | University Of Virginia Patent Foundation | TAG-1 and TAG-2 proteins and uses thereof |
| ES2346978T3 (es) | 2003-11-04 | 2010-10-22 | Novartis Vaccines And Diagnostics, Inc. | Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple. |
| PL2149585T3 (pl) | 2003-11-04 | 2014-01-31 | Novartis Vaccines & Diagnostics Inc | Zastosowanie antagonistycznych przeciwciał monoklonalnych anty-CD40 |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| CN1942201B (zh) | 2004-02-17 | 2012-06-20 | 先灵公司 | 调节il-23活性的方法；相关试剂 |
| AU2005241020B2 (en) | 2004-05-03 | 2008-07-10 | Merck Sharp & Dohme Corp. | Use of IL-17 expression to predict skin inflammation; methods of treatment |
| US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
| AU2005289594B2 (en) * | 2004-09-27 | 2012-02-02 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| TWI363091B (en) | 2004-12-20 | 2012-05-01 | Schering Corp | Uses of mammalian cytokine; related reagents |
| HUE042561T2 (hu) | 2005-06-30 | 2019-07-29 | Janssen Biotech Inc | Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások |
| US20090142855A1 (en) | 2005-06-30 | 2009-06-04 | Wei Tang | Polynucleotides and Polypeptides of the IL-12 Family of Cytokines |
| CA2619052A1 (en) | 2005-08-25 | 2007-03-01 | Eli Lily And Company | Anti-il-23 antibiodies |
| CN101248088A (zh) * | 2005-08-25 | 2008-08-20 | 伊莱利利公司 | 抗il-23抗体 |
| EP3190125A1 (en) * | 2005-08-31 | 2017-07-12 | Merck Sharp & Dohme Corp. | Engineered anti-il-23 antibodies |
| ES2333260T3 (es) | 2005-09-01 | 2010-02-18 | Schering Corporation | Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica. |
| JP2009521933A (ja) | 2005-12-28 | 2009-06-11 | セントカー・インコーポレーテツド | 乾癬および関連障害を評価および処置するためのマーカーおよび方法 |
| DK3219328T3 (da) | 2005-12-29 | 2020-07-13 | Janssen Biotech Inc | Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| CN101472611A (zh) | 2006-06-19 | 2009-07-01 | 惠氏公司 | 调节il-22和il-17的方法 |
| CL2008000058A1 (es) | 2007-01-09 | 2008-05-23 | Wyeth Corp | Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden. |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| AU2008216090A1 (en) | 2007-02-16 | 2008-08-21 | Wyeth | Protein formulations containing sorbitol |
| SG178804A1 (en) * | 2007-02-23 | 2012-03-29 | Schering Corp | Engineered anti-il-23p19 antibodies |
| EP2059534B1 (en) | 2007-02-23 | 2012-04-25 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| JP5337055B2 (ja) | 2007-02-28 | 2013-11-06 | メルク・シャープ・アンド・ドーム・コーポレーション | 免疫性障害の処置のための組合せ治療 |
| EP2197903B9 (en) | 2007-09-04 | 2015-04-22 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| EP2212442A1 (en) | 2007-10-26 | 2010-08-04 | Galderma Research & Development | Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof |
| CA2607771A1 (en) | 2007-11-01 | 2009-05-01 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence | Humanized anti-venezuelan equine encephalitis virus recombinant antibody |
| KR20190045414A (ko) | 2007-11-30 | 2019-05-02 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| KR20160116056A (ko) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-ｉｌ-12/ｉｌ-23 항체 |
| MX2011002159A (es) | 2008-08-27 | 2011-03-29 | Schering Corp | Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria. |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| JP2012522749A (ja) | 2009-04-01 | 2012-09-27 | グラクソ グループ リミテッド | 抗ｉｌ−２３免疫グロブリン |
| US20120027799A1 (en) | 2009-04-02 | 2012-02-02 | The Johns Hopkins University | Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer |
| WO2011011797A2 (en) | 2009-07-24 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cytokine compositions and methods of use thereof |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| US20120294852A1 (en) | 2009-11-24 | 2012-11-22 | Smith Jeffrey T L | Antagonists of il-6 to raise albumin and/or lower crp |
| EP2506785A4 (en) | 2009-12-02 | 2014-10-15 | Spartek Medical Inc | LOW PROFILE SPINAL PROSTHESIS WITH A BONE ANCHOR WITH A HINGED BAR AND A VERTICAL TOWER ROD |
| GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
| PE20130041A1 (es) | 2010-02-18 | 2013-01-28 | Bristol Myers Squibb Co | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) |
| RU2012139181A (ru) | 2010-02-26 | 2014-04-10 | Ново Нордиск А/С | Стабильная композиция, содержащая антитело |
| EP2542221A4 (en) | 2010-03-01 | 2013-10-23 | Cytodyn Inc | CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF |
| EP2583098B1 (en) | 2010-06-15 | 2018-08-08 | Celgene Corporation | Biomarkers for the treatment of psoriasis |
| US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
| CN103108886B (zh) | 2010-07-20 | 2016-08-24 | 赛法隆澳大利亚控股有限公司 | 抗il-23杂二聚体特异性抗体 |
| WO2012032181A2 (en) | 2010-09-10 | 2012-03-15 | Allozyne, Inc | Novel antibody derivatives |
| EP3456740A1 (en) | 2010-11-04 | 2019-03-20 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
| GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| TW201309330A (zh) | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
| US9078894B2 (en) | 2011-02-04 | 2015-07-14 | Ab Science | Treatment of severe persistant asthma with masitinib |
| US11078265B2 (en) | 2012-05-03 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Anti-IL-23 antibodies |
| US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
| CA2906384A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Methods for treating crohn's disease using an anti-il23 antibody |
| SG10201804954UA (en) | 2013-03-15 | 2018-07-30 | Amgen Inc | Methods for treating psoriasis using an anti-il-23 antibody |
| KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| EA039598B9 (ru) | 2014-09-03 | 2022-03-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23а и фно-альфа, и его применение |
| CA2972995A1 (en) | 2015-02-04 | 2016-08-11 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
| KR102644875B1 (ko) | 2015-07-23 | 2024-03-06 | 베링거잉겔하임인터내쇼날유한회사 | Il-23a 및 b-세포 활성화 인자(baff)를 표적화하는 화합물 및 이의 용도 |
| TWI811716B (zh) | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
-
2011
- 2011-11-02 EP EP18188208.5A patent/EP3456740A1/en not_active Withdrawn
- 2011-11-02 SI SI201130958A patent/SI2635601T1/sl unknown
- 2011-11-02 MX MX2019000046A patent/MX2019000046A/es unknown
- 2011-11-02 MX MX2013005015A patent/MX343858B/es active IP Right Grant
- 2011-11-02 CA CA3017116A patent/CA3017116A1/en not_active Abandoned
- 2011-11-02 EA EA201300530A patent/EA030436B1/ru active Protection Beyond IP Right Term
- 2011-11-02 PE PE2013000951A patent/PE20141162A1/es active IP Right Grant
- 2011-11-02 KR KR1020187036509A patent/KR102049223B1/ko active IP Right Grant
- 2011-11-02 MY MYPI2013001519A patent/MY162791A/en unknown
- 2011-11-02 EP EP17179739.2A patent/EP3281954A1/en not_active Withdrawn
- 2011-11-02 AU AU2011323426A patent/AU2011323426B2/en active Active
- 2011-11-02 GE GEAP201113106A patent/GEP201706733B/en unknown
- 2011-11-02 BR BR112013011065-1A patent/BR112013011065B1/pt active IP Right Grant
- 2011-11-02 DK DK11781949.0T patent/DK2635601T3/en active
- 2011-11-02 RS RS20160762A patent/RS55161B1/sr unknown
- 2011-11-02 KR KR1020137011474A patent/KR101931591B1/ko active IP Right Grant
- 2011-11-02 ES ES11781949.0T patent/ES2593754T3/es active Active
- 2011-11-02 WO PCT/US2011/058869 patent/WO2012061448A1/en active Application Filing
- 2011-11-02 SG SG2013031745A patent/SG190006A1/en unknown
- 2011-11-02 HU HUE11781949A patent/HUE030916T2/en unknown
- 2011-11-02 NZ NZ610592A patent/NZ610592A/en unknown
- 2011-11-02 LT LTEP11781949.0T patent/LT2635601T/lt unknown
- 2011-11-02 AP AP2013006820A patent/AP3953A/en active
- 2011-11-02 EP EP11781949.0A patent/EP2635601B1/en active Active
- 2011-11-02 PL PL11781949T patent/PL2635601T3/pl unknown
- 2011-11-02 MX MX2016015419A patent/MX362039B/es unknown
- 2011-11-02 CN CN201180064083.5A patent/CN103282382B/zh active Active
- 2011-11-02 CN CN201710917166.3A patent/CN107522784B/zh active Active
- 2011-11-02 US US13/287,208 patent/US8778346B2/en active Active
- 2011-11-02 PT PT117819490T patent/PT2635601T/pt unknown
- 2011-11-02 JP JP2013537771A patent/JP6126532B2/ja active Active
- 2011-11-02 EP EP16178404.6A patent/EP3115375A1/en not_active Withdrawn
- 2011-11-02 CA CA2816950A patent/CA2816950C/en active Active
- 2011-11-02 SG SG10201604605VA patent/SG10201604605VA/en unknown
- 2011-11-02 EA EA201890548A patent/EA201890548A1/ru unknown
- 2011-11-03 TW TW100140204A patent/TWI545133B/zh active
- 2011-11-03 TW TW105114183A patent/TWI653242B/zh active
- 2011-11-03 UY UY0001033703A patent/UY33703A/es active IP Right Grant
- 2011-11-03 AR ARP110104094A patent/AR083747A1/es active IP Right Grant
-
2012
- 2012-11-02 ME MEP-2016-176A patent/ME02499B/me unknown
-
2013
- 2013-04-09 IL IL225648A patent/IL225648A/en active Protection Beyond IP Right Term
- 2013-05-02 MA MA35866A patent/MA34641B1/fr unknown
- 2013-05-24 CO CO13128280A patent/CO6801628A2/es active IP Right Grant
- 2013-05-30 EC ECSP13012649 patent/ECSP13012649A/es unknown
- 2013-11-20 HK HK18107343.9A patent/HK1247940A1/zh unknown
-
2014
- 2014-06-12 US US14/302,986 patent/US9441036B2/en active Active
-
2016
- 2016-02-29 IL IL244335A patent/IL244335A/en active Protection Beyond IP Right Term
- 2016-08-04 US US15/228,254 patent/US10202448B2/en active Active
- 2016-09-06 HR HRP20161141TT patent/HRP20161141T1/hr unknown
- 2016-09-13 CY CY20161100899T patent/CY1118014T1/el unknown
- 2016-12-16 AU AU2016273970A patent/AU2016273970B2/en active Active
-
2017
- 2017-01-13 JP JP2017003955A patent/JP6445596B2/ja active Active
-
2018
- 2018-09-24 AU AU2018236692A patent/AU2018236692C1/en active Active
- 2018-11-29 JP JP2018223469A patent/JP6758361B2/ja active Active
-
2019
- 2019-01-25 US US16/257,463 patent/US20190144534A1/en not_active Abandoned
- 2019-10-14 LU LU00132C patent/LUC00132I2/fr unknown
- 2019-10-14 HU HUS1900048 patent/HUS1900048I1/hu unknown
- 2019-10-15 LT LTPA2019518C patent/LTC2635601I2/lt unknown
- 2019-10-16 NL NL301013C patent/NL301013I2/nl unknown
- 2019-10-17 NO NO2019038C patent/NO2019038I1/no unknown
- 2019-10-17 CY CY2019040C patent/CY2019040I2/el unknown
-
2020
- 2020-10-09 US US17/066,994 patent/US20210198355A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161141T1 (hr) | Anti-il-23 protutijela | |
| HRP20191835T1 (hr) | Protutijela anti-il-36r | |
| JP2014500009A5 (hr) | ||
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| HRP20231579T1 (hr) | Anti-ctla-4 antitijela i postupci njihove upotrebe | |
| HRP20170037T1 (hr) | Ljudski proteini koji vežu antigen il-23 | |
| HRP20201633T1 (hr) | Protutijela koja se vežu na il-23 | |
| HRP20180320T1 (hr) | Protutijela koja vežu il-4 i/ili il-13 i njihova uporaba | |
| HRP20211023T1 (hr) | Anti-her2 protutijelo i njegov konjugat | |
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| HRP20201341T1 (hr) | Proteini za vezivanje na antigen st2 | |
| AR126555A2 (es) | Anticuerpos de oncostatina m humana y métodos de uso | |
| HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
| HRP20130228T1 (hr) | Antitijela s visokim afinitetom za receptor humanog il 6 | |
| HRP20150623T1 (hr) | Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen | |
| JP2020504101A5 (hr) | ||
| HRP20180776T1 (hr) | Antagonisti il17c za liječenje upalnih poremećaja | |
| JP2012116856A5 (hr) | ||
| RU2017105915A (ru) | Антитела против pd-1 | |
| HRP20210120T1 (hr) | Protutijela protiv tnf alfa i njihovi funkcionalni fragmenti | |
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| JP2018121657A5 (hr) | ||
| RU2011116927A (ru) | Антитела против интерлейкина 17 (ил-17) человека и их применение | |
| HRP20210123T1 (hr) | Protutijela protiv tnf alfa i njihovi funkcionalni fragmenti |